

Real-world clinical performance of SARS-CoV-2 point-of-care diagnostic tests: a systematic review of available trials as per April, 4, 2021

Gabriel Hawthorne^{1,2}, Adam Harvey²

¹Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom

²Diagnostics for the Real World EU, Chesterford Research Park, Saffron Walden, United Kingdom

Corresponding address: hawthornegab@gmail.com

Abstract

Point-of-care assays offer a decentralised and fast solution to the diagnosis of SARS-CoV-2 and provide benefits for patients, healthcare workers, healthcare facilities and other environments. This technology has the potential to prevent outbreaks, enable faster adoption of life-changing measures and improve hospital workflow. While reviews regarding the performance of those assays exist, a review focused on the real-life clinical performance and point-of-care feasibility of those platforms was missing. Therefore, the objective of this study is to help end users (clinicians, healthcare providers and organisations) to understand the real-life performance of point-of-care assays, aiding in their implementation in decentralised, true point-of-care facilities, or inside hospitals. 871 studies were screened in 3 major databases and 51 studies were included, evaluating 20 antigen tests and 10 nucleic-acid amplification platforms. We excluded studies that used processed samples, pre-selected populations, archived samples and laboratory-only evaluations and strongly favored prospective trial designs in our inclusion criteria. We also investigated package inserts, instructions for use, comments on published studies and manufacturers websites in order to assess feasibility of POC placement and additional information of relevance to the end user. Apart from sensitivity and specificity, we present information on time to results, hands-on time, kit storage, machine operating conditions and regulatory status. To the best of our knowledge, this is the first review to systematically evaluate POC test performance in real-life clinical practice. We found the performance of tests in clinical practice to be markedly different from the manufacturers reported performance and laboratory-only evaluations in the majority of studies. Our findings may help in the decision-making process related to SARS-CoV-2 test in real-life clinical settings.

Rationale for the review

A review focused on the real-life clinical performance and point-of-care feasibility of SARS-CoV-2 diagnostic platforms was missing, impairing the ability of individuals, healthcare providers and test providers to make informed decisions on the adoption of such platforms.

Objective(s) or question(s) the review addresses:

The objective of this study is to help clinicians, healthcare providers and organisations to understand the real-life performance of point-of-care assays, aiding in their implementation in decentralised, true point-of-care facilities or in complex hospital environments.

Introduction

In December 2019, SARS-CoV-2 was first reported in Wuhan, China, and a pandemic was declared by the World Health Organization (WHO) in March, 2020. Reverse transcription-quantitative polymerase chain reaction (RT-qPCR) is the gold standard for diagnosis of SARS-CoV-2 infection. However, this

technique has disadvantages including the requirement of centralised facilities with specific equipment for testing conduction, the requirement of highly trained personnel and a long turnaround time between sample collection to results, approaching over 48 hours in some scenarios¹. Driven by the need for diagnostic solutions during the pandemic, multiple new assays and platforms were created, including multiple fast molecular and antigen tests. The FIND SARS-COV-2 DIAGNOSTIC PIPELINE², which collates an overview of commercially available SARS-CoV-2 tests in real time, shows over 1120 results for diagnostic solutions up to June 7th, 2021.

Point-of-care (POC) diagnostic platforms are defined as diagnostic assays that can deliver results near patients, without the need for centralised laboratories or diagnostic facilities³. These platforms tend to deliver fast results, often within minutes to a few hours, enabling quicker medical decisions and facilitating timely interventions. POC diagnostic platforms are currently in use in health systems for different ends, from the bedside glucose test⁴ to the analysis of blood gases and electrolytes⁵. Besides being able to provide faster results, an important advantage of POC tests is to facilitate diagnosis in locations that previously could not have access to centralised diagnostic techniques. In the context of transmissible infectious diseases, some of these assays enable quick decisions regarding treatment and isolation requirements. Before the pandemic, POC platforms were already in use for the diagnosis of conditions such as influenza-like illnesses in different settings, including accident and emergency departments in hospitals and outpatient clinics⁶. Other assays focus on the diagnosis of sexually transmitted diseases like HIV⁷ and Chlamydia trachomatis⁸. As a consequence of the SARS-CoV-2 pandemic and the need for more diagnostic solutions, not only centralised platforms but also POC diagnostic assays have had an unprecedented expansion, especially because time from sample collection to results is key to prevent further infections and speed up the workflow inside hospitals and healthcare organisations overall.

However, POC tests can have limitations such as lack of accuracy, in the form of decreased sensitivity or specificity, increased costs, and a lower throughput compared to centralised laboratory facilities and techniques like PCR. Some tests also require a number of manual steps in preparation or computers for their execution, which can make platforms complex for true POC placement. Additionally, tests that are deemed inaccurate can have multiple consequences. False negative results can cause inadequate placement of patient in hospitals (e.g, moving a infectious patient to a ‘green ward’), causing new outbreaks in an already diseased population, and also deem a community patient not infectious, thus increasing the chances of propagating infection to contacts. False positive results can inversely place patients in high-risk environments in hospitals (e.g, inside a ‘red ward’) and cause unnecessary isolation and economic impact for in an outpatient setting. If a test is flagged as inaccurate and it is decided that this test needs confirmation before the results can be trusted, no clinical action can be taken until this confirmation is obtained, which defeats the purpose of a fast test.

The regulatory aspect of novel tests during a pandemic scenario has been complex and the dimension of this process during the SARS-CoV-2 pandemic was unprecedented. Due to the urgent need for testing solutions, many abbreviated validation studies were accepted by the scientific community and by regulatory agencies such as the FDA with initial or partial evaluations, and few platforms have had their real-life performance assessed before being released to the market. Despite showing good accuracy in internal laboratory validations, multiple POC platforms for SARS-CoV-2 diagnosis had a lower-than-expected performance once released for clinical use⁹. This topic was the subject of political and juridical debate¹⁰ and resulted in some previously approved tests being later revoked from the market¹¹. There are many examples of disparities between manufacturer claims and laboratory-only evaluations and data from clinical trials. For instance, the platform ID Now (Abbott) claim a sensitivity of 100% and a specificity of

100% on the product's package insert¹², but clinical evaluations have showed sensitivities below 50%¹³ or 75%¹⁴. Another example is the study conducted by Jokela et al¹⁵, where the Mobidiag Novodiag had 93.4% (100/107) sensitivity in archived samples but only captured 60% (3/5) positive samples in a clinical setting (the clinical study could not obtain more positive samples due to a decline in prevalence).

It is well known that results from laboratory-only evaluations differ from results of clinical studies. Usually, evaluating an intervention in patients in real-life scenarios has an increased level of complexity. In the particular situation of SARS-CoV-2 testing, there are many possible reasons for those discrepancies. The first group of differences stem from factors related to the patients themselves, such as tolerance to swabbing and the presence of inhibitors in the nasopharynx secretions. There has been debate regarding the reliability of viral load and Ct values¹⁶, suggesting that viral load may greatly vary not only with the stage of the disease but also depending on the quality of swab collection and elements like dilution of swabs in a buffer and the RNA extraction process; therefore, it appears to be important for a platform to have a low limit of detection regardless of the 'average' viral load in a group of patients to miss as little cases as possible. The presence of inhibitors on samples is also relevant, as many platforms describe interactions between food, beverages and medications and their amplification chemistry in their instructions for use or package inserts¹². Once a sample is already known positive (with a known Ct value or an estimation of viral load) and has been selected in a panel for a comparison against other platform, this risk of poor-swabbing technique and inhibitors become non-existent, and therefore laboratory only evaluations may report higher sensitivity than what would be expected in a clinical setting.

Another group of differences is related to the feasibility of the workflow of the proposed testing platform in a true POC scenario, including the technique of swab collection and the expertise needed to conduct testing (such as sample preparation, machine operation, and cleaning). Many tests that claim the possibility of use in a true POC setting would find resistance to adoption due to technical complications, as it is the case of most Loop mediated isothermal amplification (LAMP) assays (e.g, Yamazaki et al¹⁷). There are also factors related to the particularities of the pandemic scenario and the precautions needed to prevent cross-infections, including the desirable use of viral inactivation techniques in samples and the unfeasibility of amplification techniques that may end up releasing amplicons in a proper clinical setting, thus possibly increasing false-positive results. Furthermore, there are differences between laboratory evaluations and clinical settings; pre-selection of samples and repeating experiments is possible in a laboratory setting, but much harder inside a clinical workflow. On top of that, the risk of false-positives in hospitalar environments is elevated, especially in areas of high movement and turnover like emergency departments, outpatient settings and clinical wards.

POC diagnosis plays an important role in SARS-CoV-2 management. Faster diagnosis speeds up isolation measures and therefore the prevention of new outbreaks. In the same way, faster confirmation of SARS-CoV-2 absence helps avoiding unnecessary isolation for individuals and their contact groups, providing social and economic benefit. The workflow of patients inside a hospital can be greatly facilitated by using tests that are reliable and provide a fast result, aiding in the placement of patients inside red or green wards and preventing SARS-CoV-2 nosocomial spread while freeing up rooms and improving the capacity of emergency departments. For example, in the study conducted by Collier et al using the SAMBA platform¹⁸, mean length of stay on COVID-19 "holding" (or "amber") wards was reduced by nearly 30h using the POC test. Additionally, timely interventions like the use of dexamethasone in patients requiring respiratory support¹⁹ or the use of interleukin-6 receptor antagonists in critically ill patients²⁰ benefit from a fast diagnostic modality, especially considering the waiting-time for a centralised test result can be up to 48h in some centres.

In this review, we are going to address the POC platforms for SARS-CoV-2 diagnosis, which can be divided into molecular tests (that use some sort of nucleic acid amplification) and antigen tests (that target SARS-CoV-2 antigens), focusing especially on clinical trials of their performance in real life settings. Our criteria was rigidly tailored to exclude samples that were pre-selected and testing conducted in laboratory conditions with frozen samples. The objective of this study is to help clinicians, healthcare providers and organisations to understand the real-life performance of POC assays, aiding in their implementation in decentralised, true point-of-care facilities or in more complex healthcare environments with safety.

Other reviews of point-of-care assays targeting SARS-CoV-2 exist and use different inclusion criteria for studies. Dinnes et al²¹ have published a review that includes 64 studies for 16 antigen platforms and 5 molecular assays, with data up to September 2020. This study attempted to divide the studies between symptomatic and asymptomatic individuals, and also included laboratory-only evaluations and retrospective studies, which escapes our goal. Yoon et al²² conducted a study using the FDA Emergency Use Authorization (FDA-EUA) authorized point-of-care tests up to August, 2020, in which 26 studies were analysed. Hayer et al²³ reviewed antigen tests but only included assays not needing a separate reader. Considering the novelty of the topic, we encourage readers to evaluate these and other studies to obtain a clearer picture of the field. Other POC diagnostic technologies that have been in use in the management of COVID-19 patients, like the use of POC ultrasound for patient follow-up after diagnosis, escape the scope of this work.

1. Methodology

This systematic review was conducted following Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines.

After debate between the authors, a broad search phrase was defined with the intention to capture a large number of studies, given the novelty of the field. Filtering results by date using the abovementioned algorithm was not necessary, since the name SARS-CoV-2 was coined after the identification of the pathogen in 2019.

2.1 Search strategy

MEDLINE database was searched on 04/04/2021 for 345 results. The algorithm used was “((point-of-care) AND (SARS-CoV-2)) AND (performance) OR ((point-of-care) AND (SARS-CoV-2)) AND (evaluation)”.

MedRxiv database was searched on 04/04/2021 for 365 results. The algorithm used was “((point-of-care) AND (SARS-CoV-2)) AND (performance) OR ((point-of-care) AND (SARS-CoV-2)) AND (evaluation)”.

BioRxiv database was searched on 04/04/2021 for 54 results. The algorithm used was: “((point-of-care) AND (SARS-CoV-2)) AND (performance) OR ((point-of-care) AND (SARS-CoV-2)) AND (evaluation)”.

2.2 Exclusion criteria

- Study is unrelated to point-of-care testing;
- Platform is not point-of-care (e.g requires the use of centralised equipment);
- Test main focus is not acute diagnosis (e.g antibody assays);

-Study is not a clinical trial (e.g proof of concepts, validations, studies conducted with frozen samples, test conducted in laboratory conditions);

-Samples extracted from patients were processed before testing;

-Population was fully pre-selected (e.g, only known positives were enrolled);

2.3 Selection process

2.31 Defining a point-of-care assay

The definition of a point-of-care diagnostic assay is not straightforward, since there are no rigid criteria for reference. The defining factor is being able to provide a diagnostic solution near the patient, thus removing the need for a centralised processing facility. While some platforms are totally mobile, being able to travel to the patient's location, and thus clearly defined as POC, others require the use of an energy source, centralised computers, or tablets. Other platforms require multiple preparation steps before test conduction (such as the need for RNA extraction, the use of a centrifuge, heating blocks or multiple pipetting steps), even though the final testing step can theoretically be conducted near the patient - this is the case of most LAMP platforms. On top of that, requirements for isolation and measures for preventing infection spread further complicated this definition during the SARS-CoV-2 pandemic. We therefore recognize the definition of a POC platform has level of subjectivity. Aligned with our objectives, in this review, we considered an outpatient community setting as our reference point. Therefore, assays that use reagents that require processing in a central laboratory or facility were excluded from our analysis. The rationale for that is that these platforms could not be operational without such facilities in the vicinity and therefore could not be implemented in the community in a truly POC fashion. Based on the information available in publications and manufacturer manuals, platforms that are judged to be technically capable of community implementation will be included and have their potential limitations/considerations (e.g, the requirement for cold chain storage or the need for a desktop computer) described in the comments of our results table.

2.32 Defining our target trials and comments about the criteria

Because of the disruption and urgency caused by the pandemic, many studies have not followed rigid clinical trial designs, and a high level of heterogeneity between the methods and designs was noticed. Issues such as need for self-isolation, patient discomfort upon repeated swabbing, multi-platform evaluations and insufficient number of positive samples during low-incidence scenarios affect the feasibility of the studies and need to be taken into consideration when proposing a review. For instance, the study of Tu et al²⁴ evaluating the ID NOW platform (Abbott) had an original design to enroll 200 positive patients, but a prevalence drop made the study unaffordable. Given the heterogeneity of the trials, finding a rigid, unifying criteria for inclusion was difficult and would make this review impossible.

In this work, as mentioned, our goal is reviewing the efficacy of the platforms in real life scenarios. Therefore, we included studies that tested platforms in real patients in a true point-of-care fashion and excluded laboratory-only evaluations. As a consequence, we have excluded from our analysis all proof-of-concept papers and studies that used spiked samples. We have also excluded platforms that used solely pre-tested frozen samples, as we understand that these conditions are vastly different from conditions found in the field; as mentioned before, the selection of frozen samples may remove samples with inhibitors, invalid or borderline results, and with low viral-loads, favoring samples with high Ct values.

Naturally, many trials used cooled or frozen samples at some point, especially when considering multi-platform evaluations. We tended to consider time from sample collection to testing in our selection

criteria; while it was impossible to decide on a clear cut-off time, this was often informative. Samples that were stored for a brief period of time to allow testing with a POC platform were accepted. While this likely does not have the same value as immediate point-of-care testing, it is often a necessary accommodation for validation studies where a comparator assay is used. As an example, Lephart et al collected samples from 88 patients (13 of which were known positive), stored at 4 °C and tested within 24h; this study was included in our table. On the other hand, studies using samples that were part of frozen panels tested in retrospect, often weeks after sample collection, tended to be excluded. As an example of our criteria, we did not include the work by Corman et al²⁵ who have conducted a comparison of seven SARS-CoV-2 antigen tests available in Europe because processed samples were used and only negative swabs were collected from real patients. Therefore, we strongly favored prospective studies.

Given the heterogeneity of designs and the conditions for studies, we debated between authors before inclusion when methods were not clear. For instance, Cerutti et al conducted a trial with 330 patients and only a minority of frozen samples was included (n = 13); this trial was included in our criteria²⁶. In the other hand, a prospective study by Courtellemont et al²⁷ was not included in analysis as known positive patients were pre-selected to enroll; therefore, operators knew the status of the patients beforehand. A similar situation happened in the study conducted by Ghofrani et al²⁸, which conducted an comparison with known positive patients and selected eligible samples; the methodology of this study was not clear and the sensitivity, reported as 96.7%, is much higher than usually reported in literature for antigen assays²⁹.

The vast majority of studies used nasopharyngeal samples, although a few studies used nasal samples only. Studies evaluating point-of-care assays using saliva samples do exist^{30,31} and usually to show a decreased performance; for instance, Basso et al³² found a sensitivity of only 13% testing saliva on antigen tests; similarly, performance of saliva samples was inferior in the study by Agulló et al³³ evaluating the Panbio assay. We therefore reported the results for either nasopharyngeal or nasal swabs and (as per manufacturer's advice) when they were part of an assessment with multiple samples. When collection methods were compared (e.g. sensitivity of self-swab against healthcare collection^{34,35}), we reported the results obtained by professional swabbing.

We also excluded studies where POC assays were compared to other POC assays, as we understand no proper gold-standard was employed in those situations. An example is the study conducted by Basu et al³⁶, where Abbott ID Now COVID-19 was compared against the Cepheid Xpert Xpress SARS-CoV-2 without a PCR standard. It is important to mention that the reliability of the gold-standard was questioned in some studies³⁷; ideally, a reference standard would be built using more than one assay¹³, cross-checked clinical information, radiological evidence and other laboratory information (e.g antibody production, viral markers or inflammatory makers), but this is understandably complex and unfeasible in many scenarios.

We also carefully considered the population type in the studies. Naturally, testing known-positive patients presents a bias. Due to challenges imposed by factors such as lockdowns, the urgency needed for results, different prevalence levels, differences in viral load between different days of disease and the size of the trials, some studies tested known positive populations in order to have statistically significant data for sensitivity. If a study was done solely in known positive patients, we tended to exclude it from our table. On the other hand, studies that complemented a prospective evaluation by testing positive populations in a randomized way were accepted, provided the proportion was reasonable. As an example, Basso et al tested antigen assays in 139 selected inpatients (this population had a 60% positivity rate) and 96 outpatients prospectively (3% positivity rate); we included this study in our table. Some studies tested exclusively in a paediatric population, and were also included³⁸.

Taking these factors into consideration, trials were judged on the overall level of heterogeneity in their methodology. In the study conducted by Osterman et al³⁹ evaluating 2 antigen platforms, there was a significant variability between 2 sites as samples were collected in different time-frames (site 1 from March to October 2020 and site 2 between November-December 2020) and some samples in site 1 had different storage methods, with some being frozen for days before testing. After discussion, we decided to include this study in our table. Other studies like Marti et al⁴⁰ were excluded due to a high level of heterogeneity in their methods, using both a POC and a centralised PCR as their standard and using different populations, including a population of known positive individuals. We attempted to include detailed explanations of the reasons for inclusion or exclusion of individual trials in the next section of this review.

2.33 Technical information on platforms

We investigated package inserts, instructions for use, comments on published studies and manufacturers websites in order to assess feasibility of POC placement and additional information that may be relevant to the end user. Apart from sensitivity and specificity, we included time to results, hands-on time, kit storage, machine operating conditions and regulatory status in the table. We also made comments on testing requirements and additional details that were deemed relevant. We opted to use publicly available information, such as the instructions for use in the FDA website¹², when possible; when that information was unavailable, we attempted to obtain the package insert by contacting the manufacturers or looking at public information published by hospitals, government entities and other third-party institutions using the platform.

2. Results




Figure 1: identification, screening, eligibility, exclusion criteria and studies included in this review

3.1 Excluded studies and studies debated between authors

Multiple studies were excluded in our final screening as tests were conducted using spiked or synthetic samples. The study by Zheng et al⁴¹ evaluating an unnamed lateral flow dipstick assay is one example. Another example is the work of Tanida et al⁴², evaluating the ARIES SARS-CoV-2 Assay; this study was excluded as the comparison was made against another POC assay (Xpert Xpress SARS-CoV-2) and used patient samples with defined copy numbers and synthetically spiked samples.

As the case of most LAMP assays, the saliva LAMP assay proposed by Yamazaki et al¹⁷ was not deemed to be feasible in a true point-of-care scenario as it requires RNA extraction, a heat block and apparently multiple pipetting steps, and therefore a reasonable level of expertise. The assay was also tested with pre-selected samples. The study by Yoshikawa et al⁴³ is another example of an excluded study using LAMP technology.

The study conducted by Peto et al⁴⁴ regarding the LamPORE platform was not included in the analysis as the platform was not deemed to be POC. RNA needs to be extracted and primers have to be added and incubated with a thermocycler, followed by multiple manual steps. The trial also was conducted with pre-selected, frozen samples. For similar reasons, the study by Singha et al⁴⁵ using a glucose meter to detect SARS-CoV-2 was not included, as the test requires a centrifuge, a magnet, and incubation in water baths. This evaluation was also conducted with known positive samples only.

Agulló et al evaluated nasopharyngeal, nasal only, and saliva samples against nasopharyngeal samples in the Cobas z 480 Analyzer (Roche). Because of this division, sample size ended up being small and heterogeneous. The concordance for positive results was 57.3% for nasopharyngeal samples and as low as 23.1% in saliva; we included the results of the nasopharyngeal testing in our table. Studies conducted with frozen samples are available for this assay⁴⁶, but as mentioned above, were not included in our review.

Basso et al³² tested antigen assays in both saliva and NPS in a mixed population (139 inpatients, 96 outpatients), providing individual figures of sensitivity and specificity for the NPS samples. Since the comparator gold-standard was also tested in saliva and NPS, the ultimate gold standard was unclear. In the case of antigen tests, the detailed number of individuals to give the figures for sensitivity and specificity were not provided in the study or in the supplementary material to the best of our knowledge. We decided to include this study in our table with a commentary pointing towards the fact that the number of individuals used to make the figures was an estimation made for practical purposes and was not provided in the original paper; therefore, it may reflect slightly different patient numbers.

Halfon et al⁴⁷ study was not included as samples were pre-selected based on symptom onset and Ct value. Similarly, the study conducted by Jääskeläinen et al⁴⁸ evaluating 3 antigen platforms was not included due to the use of pre-selected, known-positive frozen samples.

An unnamed antigen test by R-Biopharm was also evaluated by Toptan et al⁴⁹ but this study was not included in our table given that testing was conducted in archived samples only. In line the same criteria, the evaluation of the SIENNA™ COVID-19 Antigen test by Bouassa et al⁵⁰ was not included in our table as the comparison was made in the laboratory with frozen samples. The study by Mitchell and George⁵¹ evaluating the ID NOW assay and the study by Assennato et al⁵² evaluating the SAMBA-II platform were excluded for the same reasons. The study by Stevens et al⁵³ evaluating the Cepheid Xpert Xpress SARS-CoV-2 assay was also not included given the analysis was made on frozen, pre-selected samples. Consequently, the study by Young et al⁵⁴ assessing BD Veritor and the Sofia 2 SARS Antigen test was excluded as samples were shipped frozen and evaluations happened in a laboratory setting. Miscio et al⁵⁵ evaluated the bKIT Virus Finder COVID-19™ (Hyris Ltd); this study used frozen samples which were further manipulated, and therefore was not included in our list of trials.

Hoehl et al⁵⁶ study using the RIDA® QUICK SARS-CoV-2 (R-Biopharm) was not included as a minimal number of samples were tested with a confirmation method, and thus false negative results could not be determined.

The study by Mlcochova et al⁵⁷ was not included in our table because (1) the methodology used frozen pre-selected samples, (2) antibodies were evaluated together with NAAT tests, making the selected time-frame for analysis questionable (NAAT was used to test samples up to 28 days after symptoms), (3) the criteria used for the reference standard was not entirely clear and (4) the number of samples was small (n=45). For similar reasons, the study by Veyrenche⁵⁸ et al was not included in our list.

The study by Micocci et al⁵⁹ regarding the POC KIT™ Central Nucleic Acid Analyzer was not included as the low number of positives prevented the study from being a proper diagnostic accuracy study; the objective was to evaluate the feasibility of POC testing in care homes in England.

After discussion between authors, the study by Olearo et al⁶⁰ that evaluated 4 antigen tests was not included in the table for having openly deviated from the manufacturers recommended sample matrix/handling instructions and presenting a sensitivity between 49.4-54.9% , which is on the lower side of what is expected for antigen tests.

The methodology in the study by Hogan et al⁶¹ evaluating the Mesa Accula assay (now the Thermo Scientific™ Accula™ SARS-CoV-2 Test after acquisition by Thermo Fisher) was not totally clear, since there is no mention of frozen samples or time to test after sample collection. However, it appears that samples were pre-selected (N=100) and tested in a laboratory after being tested by a centralised PCR assay. We therefore believe that this study, which showed a sensitivity of 68% and a specificity of 100%, is unlikely to accurately reflect results in the field.

A different methodology was used by Rastawicki et al⁶² evaluating the PCL COVID-19 Ag rapid fluorescent immunoassay (FIA); 4 swabs were collected in the course of 2 days and antibodies were also evaluated. We considered the comparison between RT-PCR and antigen test straightforward enough for the trial to be included in our table, despite the low number of patients enrolled.

The study by Regev-Yochay⁶³ could not be included as multiple antigen platforms were classified as a whole, and individual data for individual assays was not available.

The study by Smithgall et al⁶⁴ regarding the Cepheid Xpert Xpress and Abbott ID Now was not included as only remnant patient samples were tested; therefore, the platforms were not evaluated in a proper clinical environment. Loeffelholz et al⁶⁵ study evaluating the Xpert Xpress SARS-CoV-2 was excluded as all but one site tested the platform with remnant frozen samples. The study by Wolters et al⁶⁶ on the same platform was also excluded as it only evaluated diluted and processed sample panels in a laboratory setting.

Jokela et al¹⁵ has made two different evaluations of the Novodiag by Mobidiag where, by our understanding, an initial phase was a laboratory evaluation and the second phase was a prospective clinical trial. However, there was a major drop in prevalence in the second phase of the study, which only enabled collection of 5 positive samples in a population of 362 individuals. We included the second phase of this trial in our table despite the low number of positive samples.

Moeren et al⁶⁷ study evaluating the BD Veritor antigen test had a mixed design, where 352 symptomatic adults were evaluated prospectively and known-positive individuals (n = 123) were added to the pool, visiting them at home within 72h of their RT-PCR positive result. Because the assay was tested in a true point-of-care fashion and this was necessary to obtain statistical significance, we decided to include this

study in our table. We also reported the specificity considering the 2 false-positive results obtained by the analyser, not considering the eye readings.

3.2 Comments on reference standards, sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV)

POC tests have to be compared against a selected gold-standard in order to have their performance evaluated. This standard is PCR in the vast majority of the studies (as mentioned above, some studies used another POC platform as a comparison and were excluded from our analysis). It is important to understand that the performance numbers reflect values against a reference standard, which is not always necessarily better or more accurate than the object of study. Most studies used a third platform as a tie-breaker in this context and the results of this full analysis were considered whenever the authors identified this was the case. As mentioned previously, if a clear reference standard was used using antibodies and/or clinical and radiological evidence, this was also taken into consideration.

Positive predictive value (PPV) and negative predictive value (NPV) are useful to understand how much a result can be trusted given the prevalence of a disease in a certain time. Assays are always trialed in a setting with an estimated prevalence in a given time, and for diagnostic assays, the own study results with the reference method provide an estimation of the prevalence in the tested population. PPV and NPV change accordingly depending on the prevalence of the setting. For instance, the study of an antigen test by Peña et al⁶⁸ reported a sensibility of 69.86%, a specificity of 99.61%, but a PPV of 94.44% and a NPV of 97.22% given the prevalence in that setting was 8.64%. In this work, we avoided using PPV and NPV projections whenever possible and aimed to report the provided ‘sensitivity’ and ‘specificity’ values, even though we recognize these values are intertwined. The decision to not use PPV and NPV projections was made because (1) in rapidly contagious diseases like SARS-CoV-2, an accurate real-time monitoring of prevalence parameters is difficult, in contrast to what is found for diseases with a clearly defined and predictable epidemiology; therefore the prevalence of SARS-CoV-2 infection in a given setting may change rapidly considering outbreaks, lockdowns, and new variants, (2) an accurate real time monitoring of SARS-CoV-2 regional prevalence is challenging even for developed countries, resulting in prevalence values that are often retrospective (3) an assay performance can be distorted using different prevalence levels and (4) an analysis including multiple PPV and NPV projections would make this study more speculative and less practical. We strongly suggest that the referenced trials are read in full for further information and clarification of performance as the term ‘sensitivity’ and ‘specificity’, as reported in this review, are always relative to prevalence in the particular setting of the study.

3.3 Included studies

We present the included studies in tables below. NAAT tests are grouped separately from antigen tests and have a column with testing requirements. While most manufacturers used viral RNA copies/ml in a dilution to assess platforms limit of detection, some manufacturers used plaque forming units (PFU) instead of viral RNA copies/ml. We presented the limit of detection in copies/ml if both information were available, but followed manufacturer’s instructions for use. The limit of detection of the different assays was converted into a copies/ml format when possible (for instance, if this value was given in copies/uL). We also did not include a claimed limit of detection for antigen assays.

NUCLEIC ACID AMPLIFICATION POINT-OF CARE TESTS WITH REAL-LIFE CLINICAL EVALUATIONS (PART 1)					
	Cobas Liat (Roche)	CovidNudge (DNA Nudge)	Cue COVID-19 (Cue)	ID Now (Abbott)	Novodiag (Mobidiag)

Testing requirements	Requires strict temperature control for kit storage	Requires disposable scissors (not provided by manufacturer), and an iPad; likely requires a refrigerator for kit storage	Requires strict temperature control for kit storage	-	Requires strict temperature control for kit storage
Sensitivity	100% (162/162) ⁶⁹	94% (67/71) ⁷⁰	91.7% (22/24) ⁷¹	48% (12/25) ¹³ 74.73% (139/186) ¹⁴ 91% (30/33) ⁷² 91.3% (21/2) ²⁴	60% (3/5) ¹⁵
Specificity	97.4% (190/195) ⁶⁹	100% (315/315) ⁷⁰	98.4% (239/243) ⁷¹	99.4% (336/338) ¹⁴ 100% (63/63) ¹³ 100% (151/151) ⁷² 100% (762/762) ²⁴	99.7% (355/356) ¹⁵
Claimed limit of detection	12 copies/ml ¹²	5000 copies/ml ⁷³	1300 copies/ml ¹²	125 copies/ml ¹²	313 copies/ml ⁷⁴
Time to results	~20 minutes ¹²	75 minutes ⁷³	25 minutes (post pre-heating) ¹²	13 minutes or less ¹²	80 min ⁷⁵
Hands on time	1 minute ¹²	1 minute ⁷³	1 minute ¹²	2 min ¹²	1 min ⁷⁴
Kit storage	2-8°C ¹²	25°C or less ⁷³	15-30°C ¹²	2-30°C ¹²	18-25°C ⁷⁴
Machine operating conditions	15-30°C ¹²	16-30°C ⁷³	15-30°C ¹²	15-30°C ¹²	15-30°C ⁷⁴
Regulatory status	FDA EUA, CE ¹²	N/A	FDA EUA ¹²	FDA EUA, CE ¹²	CE ⁷⁵
Additional Details	For the only trial fitting criteria available for this platform, Invalid specimens on Liat testing were excluded (n = 3). FDA Issued risk of false positives from leaking tubes ⁷⁶	Invalid rate of 5.7%. Report from March 2021 from the UK's government Department of Health and Social Care shows a sensitivity of 82.1% and a specificity of 99.1% after evaluation in 11 sites (details unpublished) ⁷⁷	8.6% invalid/cancelled results (25/292) ⁷¹	-	-

N/A = not available

NUCLEIC ACID AMPLIFICATION POINT-OF CARE TESTS WITH REAL-LIFE CLINICAL EVALUATIONS (PART 2)					
	QIAstat-Dx (Qiagen)	RapiPrep (MicrosensDx)	SAMBA-II (Diagnostics for the Real World)	VitaPCR (Credo)	Xpert Xpress (Cepheid)
Testing requirements	Requires strict temperature control for kit storage	Details unclear	Requires a tablet for test conduction; relatively long time to results	Requires strict temperature control for kit storage	Likely requires a refrigerator for kit storage; it requires a computer for results delivery of results ¹² .
Sensitivity	100% (23/23) ⁷⁸	80% (8/10) ⁷⁹	96.9% (31/32) ¹⁸	90% (126/140) ⁸⁰ 99.3% (155/156) ³⁷	100% (25/25) ¹³
Specificity	90% (18/20) ⁷⁸	73% (8/11) ⁷⁹	100% (117/117) ¹⁸	94.7% (358/378) ³⁷ 99% (98/99) ⁸⁰	97% (60/62) ¹³
Claimed limit of detection	500 copies/ml ¹²	N/A	250 copies/ml ⁸¹	2730 copies/ml ⁸²	0.0200 PFU/mL (plaque forming units) ¹²
Time to results	67 min ¹²	25 min on average ⁷⁹	86-101 min ⁸¹	20 min ⁸²	30-45 min ⁸³
Hands on time	1 min ¹²	N/A	1 min ⁸¹	1 min ⁸²	1 min ⁸³
Kit storage	15-25°C ¹²	N/A	2-37°C ⁸¹	15-30°C ⁸²	2-28°C ¹²
Machine operating conditions	15-30°C ⁸⁴	N/A	10-38°C ⁸¹	10-38°C ⁸²	15-30°C ¹²
Regulatory status	FDA, CE ¹²	N/A	CE ⁸¹	CE ⁸²	FDA EUA, CE ⁸³
Additional Details	Multi-pathogen assay, tests 22 pathogens ¹²	Test consists of extraction followed by RT-LAMP; details are unclear ⁸⁵	-	-	Gene E is not specific for SARS-CoV-2; samples exclusively positive for E gene need retesting (presumptive positive results) ¹²

N/A = not available

ANTIGEN POINT-OF CARE TESTS WITH REAL-LIFE CLINICAL EVALUATIONS (PART 1)				
	AAZ-LMB	BINAXnow	PANBIO (Abbott)	mariPOC SARS-

	COVID-VIRO® (AAZ)	(Abbott)		CoV-2 (ArcDia)
Sensitivity	84.1% (116/138) ⁸⁶	77.4% (226/292) ⁸⁷	38.6% (39/101) ⁸⁸ 48.1% (38/79) ⁸⁹ 46.67% (7/15) ⁹⁰ 57% (76/132) ³³ 60.5% (118/195) ⁹¹ 66% (58/88*) ³² 66.4% (148/223) ⁹² 71.4% (100/140) ⁹³ 73.3% (44/60) ⁹⁴ 74% (186/250) ⁹⁵ 77.7% (14/18) ³⁸ 79.6% (43/54) ⁹⁶ 82.1% (602/733) ⁹⁷ 84% (59/70*) ⁹⁸ 85.5% (106/124) ⁹⁹ 86.1% (101/122) ⁸⁶ 86.8% (92/106) ¹⁰⁰ 86.1% (249/268) ¹⁰¹ 90.5% (325/359) ¹⁰²	92.3% (12/13) ¹⁰³
Specificity	100% (186/186) ⁸⁶	99.4% (2002/2016*) ⁸⁷	98% (56/57*) ⁹⁸ 98.8% (592/599) ¹⁰² 99% (145/146*) ³² 99.1% (3420/3450) ⁹⁷ 99.5% (184/185) ⁸⁸ 99.61% (3146/3158) ⁹⁰ 99.8% (519/520) ³³ 99.8% (1220/1222) ⁹³ 99.9% (1000/1001) ¹⁰⁰ 99.9% (3738/3741) ⁹⁵ 99.9% (1341/1343) ¹⁰¹ 100% (217/217) ⁸⁹ 100% (368/368) ⁹² 100% (369/369*) ⁹⁶ 100% (422/422) ³⁸ 100% (195/195) ⁹⁴ 100% (709/709) ⁹¹ 100% (149/149) ⁸⁶ 100% (411/411) ⁹⁹	100% (198/198) ¹⁰³
Time to results	15 min ¹⁰⁴	15 min ¹²	15-20 min ¹⁰⁵	20-55 min ¹⁰⁶
Hands on time	3 min ¹⁰⁴	1 min ¹²	5 min ¹⁰⁵	N/A
Kit storage	2-30 °C ¹⁰⁴	2-30 °C ¹²	2-30 °C ¹⁰⁵	N/A
Machine operating conditions	Nil (cassette) ¹⁰⁴	Nil (antigen card) ¹²	Nil (cassette) ¹⁰⁵	N/A
Regulatory status	CE ¹⁰⁴	FDA ¹²	CE/WHO EUL ¹⁰⁵	CE ¹⁰⁶
Additional Details	-	-	Reagents must be brought to room temperature 30 min before use when stored in a refrigerator ¹⁰⁵	-

N/A = not available

*numbers were calculated based on information on paper but not explicitly provided by authors.

ANTIGEN POINT-OF CARE TESTS WITH REAL-LIFE CLINICAL EVALUATIONS (PART 2)						
	2019-CoV Ag Fluorescence Rapid Test Kit (Bioeasy)	BD Veritor (BD)	COVID-19 antigen Respi-Strip (Coris)	QuickNavi™ -COVID19 (Denka)	ESPLINE rapid test (Fujirebio)	SARS-CoV-2 Antigen (Innova)
Sensitivity	66.7% (10/15) ¹⁰⁷	80.7% (112/140) ^{*67}	37.1% (13/35) ¹⁰⁸ 50% (4/8) ¹⁰⁷ 50% (47/94) ¹⁰⁹	86.7% (77/91) ¹¹⁰	48% (42/88*) ³²	86.4% (242/280) ¹¹¹
Specificity	93.1%(663/712) ¹⁰⁷	99.4% (330/332) ⁶⁷	95.8% (392/409) ¹⁰⁷ 100% (328/328) ¹⁰⁸ 100% (44/44) ¹⁰⁹	100% (1081/1081) ¹¹⁰	100% (146/146*) ³²	95.1 (426/448)% ¹¹¹
Time to results	10 min	15-20min ¹²	15-30 min ¹¹²	N/A	30 min ¹¹³	20-30 min ¹¹⁴
Hands on time	N/A	N/A	N/A	N/A	>5 min ¹¹³	2 min ¹¹⁴
Kit storage	N/A	2-30°C ¹²	4-30°C ¹¹²	N/A	2-30°C ¹¹³	2-30°C ¹¹⁴
Machine operating conditions	Nil (Ag cassette)	2-30°C ¹²	Nil (Ag cassette)	N/A	Nil (Ag cassette)	Nil (Ag cassette)
Regulatory status	N/A	FDA ¹²	CE ¹¹²	N/A	CE ¹¹³	CE ¹¹⁴
Additional Details	-	-	-	-	-	-

N/A = not available

*numbers were calculated based on information on paper but not explicitly provided by authors.

ANTIGEN POINT-OF CARE TESTS WITH REAL-LIFE CLINICAL EVALUATIONS (PART 3)					
	SARS-CoV-2 Antigen Rapid Test Kit (Lepu Medical)	LumiraDx SARS-CoV-2 (LumiraDx)	MEDsan® SARS-Cov-2 (MEDsan)	NADAL® COVID-19 (Nal vonminden)	PCL COVID-19 Ag rapid (PCL)

Sensitivity	45.5% (46/101) ⁸⁸	82.2% (120/146) ¹¹⁵ 97.5% (39/40) ¹¹⁶	36.51% (23/63) ⁹⁰	56.52% (13/23) ⁹⁰	38.9% (14/36) ⁶²
Specificity	89.2% (165/185) ⁸⁸	99.3% (611/615) ¹¹⁵ 97.7% (380/389*) ¹¹⁶	99.62% (1010/1014) ⁹⁰	100% (783/783) ⁹⁰	83% (38/46*) ⁶²
Time to results	15 min ¹¹⁷	12 min ¹²	15-20min ¹¹⁸	N/A	10min ¹¹⁹
Hands on time	>5 min ¹¹⁷	2 min ¹²	2 min ¹¹⁸	N/A	N/A
Kit storage	4-30°C ¹¹⁷	2-30°C ¹²	2-30°C ¹¹⁸	N/A	N/A
Machine operating conditions	Nil (Ag card)	15-30°C ¹²	Nil (Ag cassette)	N/A	N/A
Regulatory status	CE ¹¹⁷	CE, FDA ¹²	CE ¹¹⁸	N/A	N/A
Additional Details	Recalled from market due to likely risk of false results ¹²⁰	-	-	-	-

N/A = not available

*numbers were calculated based on information on paper but not explicitly provided by authors.

ANTIGEN POINT-OF CARE TESTS WITH REAL-LIFE CLINICAL EVALUATIONS (PART 4)					
	BIOCREDIT COVID-19 Ag (RapiGEN)	SARS-CoV-2 Rapid Antigen Test (Roche)	STANDARD Q COVID-19 Ag Test (SD Biosensor)	CLINITEST® Rapid COVID-19 Antigen Test (Siemens)	SGTI-flex COVID-19 Ag (Sugentech)
Sensitivity	56.4% (44/78) ⁶⁷	43.6% (44/101) ⁸⁸ 50.3% (224/445) ³⁹	45.4% (173/381) ³⁹ 62.3% (139/223) ⁹² 69.86% (51/73) ⁶⁸ 70.6% (77/109) ²⁶ 76.6% (36/47) ¹⁰⁷ 79.5% (31/39) ³⁵ 84.9% (158/186) ¹²¹ 85% (34/40) ³⁴ 89% (170/191) ⁹⁹ 92.9% (104/122) ⁸⁶	51.5% (52/101) ⁸⁸ 73.5% (78/106)* ¹²²	52.6% (41/78) ¹²³

Specificity	100% (28/28) ¹²³	96.2% (178/185) ⁸⁸ 97.7% (377/386) ³⁹	97.8% (352/360) ³⁹ 99.1% (105/106) ³⁴ 99.3% (1207/1216) ¹⁰⁷ 99.5% (366/368) ⁹² 99.5% (780/784) ¹²¹ 99.6% (249/250) ³⁵ 99.61% (766/769) ⁶⁸ 99.7% (337/338) ⁹⁹ 100% (221/221) ²⁶ 100% (221/221) ⁸⁶	98.4% (182/185) ⁸⁸ 100% (164/164)* ¹²²	96.4% (26/27) ¹²³
Time to results	15-30 min ¹²⁴	15-30 min ¹²⁵	15-30 min ¹²⁶	15 min ¹²⁷	15 min ¹²⁸
Hands on time	>5 min ¹²⁴	2 min ¹²⁵	2 min ¹²⁶	>5min ¹²⁷	N/A
Kit storage	1-40°C ¹²⁴	2-30°C ¹²⁵	2-30°C ¹²⁶	2-30°C ¹²⁷	N/A
Machine operating conditions	Nil (test device) ¹²⁴	Nil (Ag cassette) ¹²⁵	Nil (Test device) ¹²⁶	Nil (Ag cassette) ¹²⁷	Nil (Ag cassette) ¹²⁸
Regulatory status	CE ¹²⁴	CE ¹²⁵	CE ¹²⁶	CE ¹²⁷	N/A
Additional Details	-	-	-	-	-

N/A = not available

*numbers were calculated based on information on paper but not explicitly provided by authors.

3 Discussion

We identified 20 antigen platforms and 10 NAAT platforms with clinical trials that fit our defined criteria. A total of 30 platforms were covered by 51 studies, with some studies covering more than one platform. To the best of our knowledge, this is the first review to systematically evaluate POC test performance in real-life clinical practice. Considering the high heterogeneity of methods and outcomes between studies, and also the unbalanced number of studies per platform, we opted not to conduct a meta-analysis in this study. We have decided against providing an ‘average’ performance for platforms as this would likely be misleading and would potentially downplay the method discrepancies in the trials.

NAAT platforms, on average, take longer to provide results and require more equipment for test conduction compared to antigen tests. However, their results have shown to be more reliable in clinical practice. Applying selection criteria specifically targeted at prospective studies, we noticed important differences between performance reported by manufacturers and laboratory evaluations and performance in real-life conditions. While this is true for both NAAT platforms and antigen assays, the discrepancies were more extreme in the antigen group. Healthcare facilities, individuals and test providers must be aware of the real-life performance of the platforms before deciding on their implementation. We hope this systematic review can help making informed decisions regarding SARS-CoV-2 testing.

The accuracy of diagnostic tests is affected by numerous factors, including days since symptom onset, individual viral load, quality of sample collection, site of sample collection (nasopharyngeal, nasal only, pharyngeal only, saliva only) and test modality (nucleic acid amplification x antigen). As previously mentioned, all studies included were compared to PCR assays, considered the gold standard for SARS-CoV-2 diagnosis. Our results suggest a strong tendency of antigen tests to be less accurate than NAAT tests in real-life clinical trials. This finding is aligned with findings of other reviews²¹.

We also noticed differences in prevalence within the same test. For instance, the sensitivity of the antigen assay STANDARD Q COVID-19 Ag Test (SD Biosensor) varied between 45%-92%, and the sensitivity of the antigen test PANBIO (Abbott) varied between 38-90%. The explanations for the phenomenon of high variability in results, particularly in sensitivity, are likely multifactorial, including differences in SARS-CoV-2 prevalence between studies and differences in sample size and methodology. One such factor may be testing transporting and storage, as most antigen tests need to be stored between 5-30°C. Haage et al¹²⁹ assessed eleven antigen tests and identified reductions of up to 10 fold in sensitivity for 46% of the assays after 10 minutes outside the ideal temperature range; this number grew to 73% if the exposure lasted three weeks. Pollock et al⁸⁷ had similar findings evaluating the BinaxNOW test. This finding is significant and may partially explain false negative results, considering that many regions have oscillations in temperature outside the target range and some factors like stock storage and transportation are beyond the end-user control. Point-mutations generating changes in the SARS-CoV-2 nucleocapsid protein structures can also play a role; Bourassa et al uncovered a 1000-fold loss in sensitivity for the Sofia Antigen test (Quidel) which was associated with the D399N mutation¹³⁰. It is also important to point out that the high variability range in results may reflect a publishing bias, as these two platforms were the only ones with a relevant number of published studies.

Additionally, we found some evidence that the sensitivity of antigen tests increases if they are used within the first days of symptoms, but this is still significantly inferior to the average performance of NAAT tests. For instance, Bulilete et al reported that the sensitivity of the Panbio assay improved from 71.4% to 77.2% if the test was conducted in the first 5 days of symptoms⁹³. However, a division between asymptomatic and symptomatic individuals has a questionable value because a significant portion of the asymptomatic individuals are in fact pre-symptomatic and will develop symptoms in the future, but may already be in the shredding phase; this becomes even more important if the individual has had a high-risk contact. On top of that, the definition of being symptomatic is subjective and depends of factors such threshold of perception and the memory of the tested individual, which is not always reliable in settings such as care-homes and acute hospitalar settings and for population such as children and cognitively impaired individuals. Additionally, timely interventions such as the use of dexamethasone in patients requiring respiratory support depends on confirmation of SARS-CoV-2 presence¹⁹; this is usually a late clinical presentation and it is reasonable to expect a portion of patients to present late to services.

Some studies also showcased the implications of using tests with suboptimal specificity in settings of low prevalence. Hoehl et al⁵⁶ used an antigen test for the self-testing of teachers at home, with the goal to prevent clusters of infections; out of a population of 602 individuals, 5 were confirmed positive but 16 false positive results were recorded. The same concern was voiced by Kriemler et al¹³¹ when using antigen tests to assess the point-prevalence of acute SARS-CoV-2 infections in school children. In a study by Colavita et al, of 73,634 individuals in international airports, 1176 were reported antigen positive but only 34.3% of the were actually positive after NAAT test confirmation.

Regarding kit storage, most platforms will require the use of refrigerated facilities given the average upper storage limit was 30°C. Some of them deserve mention for requiring strict temperature control, particularly the Cobas Liat (2-8°C), the QIAstat-DX (15-25°C) and Novodiag (18-25°C). Only 3 platforms have a published kit storage temperature above 30°C: SAMBA-II (NAAT), VitaPCR (NAAT), and BIOCREDIT (antigen).

Time to results was highly variable between NAAT platforms, ranging from ~13 minutes (ID Now) to ~90 minutes (SAMBA-II). The time to results of antigen platforms was usually below 30 minutes.

Hands-on time, used in this context as the time needed to prepare test conduction (prepare samples, load machine, configure test conduction) was usually around 1 to 2 minutes, and rarely over 5 minutes across all platforms.

Some platforms had little information available about them, despite our best efforts to obtain package inserts or instructions for use. This was especially true for antigen tests. These platforms include the NADAL® COVID-19 (Nal vonminden), PCL COVID-19 Ag rapid (PCL), QuickNavi™-COVID19 (Denka), 2019-CoV Ag Fluorescence Rapid Test Kit (Bioeasy), SGTI-flex COVID-19 Ag (Sugentech) and mariPOC SARS-CoV-2 (ArcDia). We have therefore included information to the best of our knowledge and signaled the information we could not obtain by writing “not available” in the table.

We encourage readers to read the original studies used as the basis to our table. We also encourage the reading of other reviews of point-of-care assays targeting SARS-CoV-2 for a clearer picture of the field.

4.2 Other assays

Assays other than NAAT and antigen tests have also been used. We found a few studies using the FebriDx device (Lumos diagnostics), which captures Myxovirus resistance protein A (MxA - a marker of interferon-induced antiviral host response) and C reactive protein (a well-known and widely used inflammatory marker in medical practice). In one study, the platform had a sensitivity of 93% and a specificity of 86%¹³² (with an estimated prevalence of 48% in the studied population). There are other studies available regarding this assay^{133,134,135} but a comprehensive analysis of this platform escapes the purpose of our review. As the markers are commonly elevated for a range of pathogens, the test has a low specificity and has limited use in settings with low prevalence.

Few platforms had a satisfactory number of clinical studies, and in many situations the number of individuals enrolled was suboptimal. Further research and reviews of this topic are encouraged.

4.3 Limitations

One of the main limitations of this review is the selection criteria. Considering the high heterogeneity of methods and outcomes between studies, finding a clear-cut unified exclusion criteria was not possible. We debated between authors when in doubt, but a level of subjectivity was inevitable.

For the same reasons of heterogeneity, we opted not to conduct a meta-analysis in this study. Authors have decided against providing an ‘average’ performance for platforms as this would likely be misleading and would potentially downplay the method discrepancies in the trials.

5. Other information

5.1 Registration

This review was registered in the International prospective register of systematic reviews (PROSPERO) with registration number CRD42021260694. A protocol for this study can be assessed online.

5.2 Conflicts of interest

GHH and AH are employed by Diagnostics of the Real World, who has a molecular assay that was mentioned in this systematic review.

References

1. Weekly statistics for NHS Test and Trace (England): 24 June to 30 June 2021. *GOV.UK* <https://www.gov.uk/government/publications/weekly-statistics-for-nhs-test-and-trace-england-24-june-to-30-june-2021>.
2. SARS-CoV-2 diagnostic pipeline. *FIND* <https://www.finddx.org/covid-19/pipeline/>.
3. Kozel, T. R. & Burnham-Marusich, A. R. Point-of-Care Testing for Infectious Diseases: Past, Present, and Future. *J Clin Microbiol* **55**, 2313–2320 (2017).
4. Rebel, A., Rice, M. A. & Fahy, B. G. Accuracy of point-of-care glucose measurements. *J Diabetes Sci Technol* **6**, 396–411 (2012).
5. Allardet-Servent, J. *et al.* Point-of-Care Versus Central Laboratory Measurements of Hemoglobin, Hematocrit, Glucose, Bicarbonate and Electrolytes: A Prospective Observational Study in Critically Ill Patients. *PLoS One* **12**, (2017).
6. Mitamura, K. *et al.* Clinical evaluation of ID NOW influenza A & B 2, a rapid influenza virus detection kit using isothermal nucleic acid amplification technology - A comparison with currently available tests. *J Infect Chemother* **26**, 216–221 (2020).
7. Ritchie, A. V. *et al.* SAMBA HIV Semiquantitative Test, a New Point-of-Care Viral-Load-Monitoring Assay for Resource-Limited Settings. *Journal of Clinical Microbiology* **52**, 3377–3383 (2014).
8. Harding-Esch, E. M. *et al.* A 30-Min Nucleic Acid Amplification Point-of-Care Test for Genital Chlamydia trachomatis Infection in Women: A Prospective, Multi-center Study of Diagnostic Accuracy. *EBioMedicine* **28**, 120–127 (2018).
9. Commissioner, O. of the. Coronavirus (COVID-19) Update: FDA Informs Public About Possible Accuracy Concerns with Abbott ID NOW Point-of-Care Test. *FDA* <https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-informs-public-about-possible-accuracy-concerns-abbott-id-now-point> (2020).
10. McGinley, L. & Abutaleb, Y. Trump administration bars FDA from regulating some laboratory tests, including for coronavirus. *Washington Post*.
11. Health, C. for D. and R. Removal Lists of Tests that Should No Longer Be Used and/or Distributed for COVID-19: FAQs on Testing for SARS-CoV-2. *FDA* (2020).
12. Health, C. for D. and R. In Vitro Diagnostics EUAs - Molecular Diagnostic Tests for SARS-CoV-2. *FDA* (2021).
13. Lephart, P. R. *et al.* Comparative study of four SARS-CoV-2 Nucleic Acid Amplification Test (NAAT) platforms demonstrates that ID NOW performance is impaired substantially by patient and specimen type. *Diagnostic Microbiology and Infectious Disease* **99**, 115200 (2021).
14. Harrington, A. *et al.* Comparison of Abbott ID Now and Abbott m2000 Methods for the Detection of SARS-CoV-2 from Nasopharyngeal and Nasal Swabs from Symptomatic Patients. *J Clin Microbiol* **58**, (2020).
15. Jokela, P. *et al.* SARS-CoV-2 sample-to-answer nucleic acid testing in a tertiary care emergency department: evaluation and utility. *Journal of Clinical Virology* **131**, 104614 (2020).

16. Dahdouh, E., Lázaro-Perona, F., Romero-Gómez, M. P., Mingorance, J. & García-Rodríguez, J. Ct values from SARS-CoV-2 diagnostic PCR assays should not be used as direct estimates of viral load. *J Infect* **82**, 414–451 (2021).
17. Yamazaki, W., Matsumura, Y., Thongchankaew-Seo, U., Yamazaki, Y. & Nagao, M. Development of a point-of-care test to detect SARS-CoV-2 from saliva which combines a simple RNA extraction method with colorimetric reverse transcription loop-mediated isothermal amplification detection. *Journal of Clinical Virology* **136**, 104760 (2021).
18. Collier, D. A. *et al.* Point of Care Nucleic Acid Testing for SARS-CoV-2 in Hospitalized Patients: A Clinical Validation Trial and Implementation Study. *CR Med* **1**, (2020).
19. Dexamethasone in Hospitalized Patients with Covid-19. *New England Journal of Medicine* **384**, 693–704 (2021).
20. Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19. *New England Journal of Medicine* **384**, 1491–1502 (2021).
21. Dinnes, J. *et al.* Rapid, point-of-care antigen and molecular-based tests for diagnosis of SARS-CoV-2 infection. *Cochrane Database of Systematic Reviews* (2021) doi:10.1002/14651858.CD013705.pub2.
22. Yoon, S. H. *et al.* Point-of-care testing for the detection of SARS-CoV-2: a systematic review and meta-analysis. *Eur Rev Med Pharmacol Sci* **25**, 503–517 (2021).
23. Hayer, J., Kasapic, D. & Zemmrch, C. Real-world clinical performance of commercial SARS-CoV-2 rapid antigen tests in suspected COVID-19: A systematic meta-analysis of available data as per November 20, 2020. *International Journal of Infectious Diseases* **0**, (2021).
24. Tu, Y.-P., Iqbal, J. & O’Leary, T. Evaluation of ID NOW and RT-PCR for Detection of SARS-CoV-2 in an Ambulatory Population. *medRxiv* 2020.12.07.20245225 (2020) doi:10.1101/2020.12.07.20245225.
25. Corman, V. M. *et al.* Comparison of seven commercial SARS-CoV-2 rapid point-of-care antigen tests: a single-centre laboratory evaluation study. *The Lancet Microbe* **2**, e311–e319 (2021).
26. Cerutti, F. *et al.* Urgent need of rapid tests for SARS CoV-2 antigen detection: Evaluation of the SD-Biosensor antigen test for SARS-CoV-2. *J Clin Virol* **132**, 104654 (2020).
27. Courtellemont, L. *et al.* High performance of a novel antigen detection test on nasopharyngeal specimens for SARS-CoV-2 infection diagnosis: a prospective study. *medRxiv* 2020.10.28.20220657 (2021) doi:10.1101/2020.10.28.20220657.
28. Ghofrani, M. *et al.* Performance characteristics of the ID NOW COVID-19 assay: A regional health care system experience. *medRxiv* 2020.06.03.20116327 (2020) doi:10.1101/2020.06.03.20116327.
29. Courtellemont, L. *et al.* High performance of a novel antigen detection test on nasopharyngeal specimens for SARS-CoV-2 infection diagnosis: a prospective study. *medRxiv* 2020.10.28.20220657 (2021) doi:10.1101/2020.10.28.20220657.
30. Chen, J. H.-K. *et al.* Evaluating the use of posterior oropharyngeal saliva in a point-of-care assay for the detection of SARS-CoV-2. *Emerg Microbes Infect* **9**, 1356–1359 (2020).

31. SoRelle, J. A. *et al.* Saliva for use with a point of care assay for the rapid diagnosis of COVID-19. *Clin Chim Acta* **510**, 685–686 (2020).
32. Basso, D. *et al.* Salivary SARS-CoV-2 antigen rapid detection: A prospective cohort study. *Clinica Chimica Acta* **517**, 54–59 (2021).
33. Agulló, V. *et al.* Evaluation of the rapid antigen test Panbio COVID-19 in saliva and nasal swabs in a population-based point-of-care study. *J Infect* **82**, 186–230 (2021).
34. Lindner, A. K. *et al.* SARS-CoV-2 patient self-testing with an antigen-detecting rapid test: a head-to-head comparison with professional testing. *medRxiv* 2021.01.06.20249009 (2021) doi:10.1101/2021.01.06.20249009.
35. Lindner, A. K. *et al.* Head-to-head comparison of SARS-CoV-2 antigen-detecting rapid test with self-collected nasal swab versus professional-collected nasopharyngeal swab. *European Respiratory Journal* **57**, (2021).
36. Basu, A. *et al.* Performance of Abbott ID Now COVID-19 Rapid Nucleic Acid Amplification Test Using Nasopharyngeal Swabs Transported in Viral Transport Media and Dry Nasal Swabs in a New York City Academic Institution. *Journal of Clinical Microbiology* **58**, (2020).
37. Fournier, P.-E. *et al.* Contribution of VitaPCR SARS-CoV-2 to the emergency diagnosis of COVID-19. *J Clin Virol* **133**, 104682 (2020).
38. González-Donapetry, P. *et al.* Think of the Children: Evaluation of SARS-CoV-2 Rapid Antigen Test in Pediatric Population. *The Pediatric Infectious Disease Journal* **40**, 385–388 (2021).
39. Osterman, A. *et al.* Evaluation of two rapid antigen tests to detect SARS-CoV-2 in a hospital setting. *Med Microbiol Immunol* **210**, 65–72 (2021).
40. Marti, J. L. G. *et al.* Differences in detected viral loads guide use of SARS-CoV-2 antigen-detection assays towards symptomatic college students and children. *medRxiv* 2021.01.28.21250365 (2021) doi:10.1101/2021.01.28.21250365.
41. Zheng, Y.-Z. *et al.* Reverse Transcription Recombinase-Aided Amplification Assay With Lateral Flow Dipstick Assay for Rapid Detection of 2019 Novel Coronavirus. *Front. Cell. Infect. Microbiol.* **11**, (2021).
42. TANIDA, K. *et al.* Evaluation of the automated cartridge-based ARIES SARS-CoV-2 Assay (RUO) against automated Cepheid Xpert Xpress SARS-CoV-2 PCR as gold standard. *Eur J Microbiol Immunol (Bp)* **10**, 156–164 (2020).
43. Yoshikawa, R. *et al.* Development and evaluation of a rapid and simple diagnostic assay for COVID-19 based on loop-mediated isothermal amplification. *PLOS Neglected Tropical Diseases* **14**, e0008855 (2020).
44. Peto, L. *et al.* Diagnosis of SARS-CoV-2 Infection with LamPORE, a High-Throughput Platform Combining Loop-Mediated Isothermal Amplification and Nanopore Sequencing. *J Clin Microbiol* **59**, (2021).

45. Singh, N. K. *et al.* Hitting the diagnostic sweet spot: Point-of-care SARS-CoV-2 salivary antigen testing with an off-the-shelf glucometer. *Biosens Bioelectron* **180**, 113111 (2021).
46. Alemany, A. *et al.* Analytical and clinical performance of the panbio COVID-19 antigen-detecting rapid diagnostic test. *Journal of Infection* **82**, 186–230 (2021).
47. Halfon, P. *et al.* An optimized stepwise algorithm combining rapid antigen and RT-qPCR for screening of COVID-19 patients. *medRxiv* 2021.01.13.21249254 (2021) doi:10.1101/2021.01.13.21249254.
48. Jääskeläinen, A. E. *et al.* Evaluation of three rapid lateral flow antigen detection tests for the diagnosis of SARS-CoV-2 infection. *J Clin Virol* **137**, 104785 (2021).
49. Toptan, T. *et al.* Evaluation of a SARS-CoV-2 rapid antigen test: Potential to help reduce community spread? *J Clin Virol* **135**, 104713 (2021).
50. Bouassa, R.-S. M., Veyer, D., Péré, H. & Bélec, L. Analytical performances of the point-of-care SIENNA™ COVID-19 Antigen Rapid Test for the detection of SARS-CoV-2 nucleocapsid protein in nasopharyngeal swabs: A prospective evaluation during the COVID-19 second wave in France. *International Journal of Infectious Diseases* **106**, 8–12 (2021).
51. Mitchell, S. L. & George, K. St. Evaluation of the COVID19 ID NOW EUA assay. *J Clin Virol* **128**, 104429 (2020).
52. Assennato, S. M. *et al.* Performance Evaluation of the SAMBA II SARS-CoV-2 Test for Point-of-Care Detection of SARS-CoV-2. *J Clin Microbiol* **59**, (2020).
53. Stevens, B. *et al.* Comparison of a Point-of-Care Assay and a High-Complexity Assay for Detection of SARS-CoV-2 RNA. *The Journal of Applied Laboratory Medicine* **5**, 1307–1312 (2020).
54. Young, S. *et al.* Clinical Evaluation of BD Veritor SARS-CoV-2 Point-of-Care Test Performance Compared to PCR-Based Testing and versus the Sofia 2 SARS Antigen Point-of-Care Test. *J Clin Microbiol* **59**, (2020).
55. Miscio, L. *et al.* Evaluation of the diagnostic accuracy of a new point-of-care rapid test for SARS-CoV-2 virus detection. *J Transl Med* **18**, (2020).
56. Hoehl, S. *et al.* At-home self-testing of teachers with a SARS-CoV-2 rapid antigen test to reduce potential transmissions in schools: Results of the SAFE School Hesse Study. *medRxiv* 2020.12.04.20243410 (2020) doi:10.1101/2020.12.04.20243410.
57. Mlcochova, P. *et al.* Combined Point-of-Care Nucleic Acid and Antibody Testing for SARS-CoV-2 following Emergence of D614G Spike Variant. *CR Med* **1**, (2020).
58. Veyrenche, N. *et al.* Diagnosis value of SARS-CoV-2 antigen/antibody combined testing using rapid diagnostic tests at hospital admission. *Journal of Medical Virology* **93**, 3069–3076 (2021).
59. Micocci, M. *et al.* Is Point-of-Care testing feasible and safe in care homes in England? An exploratory usability and accuracy evaluation of a point-of-care polymerase chain reaction test for SARS-COV-2. *medRxiv* 2020.11.30.20240010 (2021) doi:10.1101/2020.11.30.20240010.

60. Olearo, F. *et al.* Handling and accuracy of four rapid antigen tests for the diagnosis of SARS-CoV-2 compared to RT-qPCR. *J Clin Virol* **137**, 104782 (2021).
61. Hogan, C. A. *et al.* Comparison of the Accula SARS-CoV-2 Test with a Laboratory-Developed Assay for Detection of SARS-CoV-2 RNA in Clinical Nasopharyngeal Specimens. *Journal of Clinical Microbiology* **58**, (2020).
62. Rastawicki, W., Gierczyński, R., Juszczak, G., Mitura, K. & Henry, B. M. Evaluation of PCL rapid point of care antigen test for detection of SARS-CoV-2 in nasopharyngeal swabs. *J Med Virol* **93**, 1920–1922 (2021).
63. Regev-Yochay, G. *et al.* Real World Performance of SARS-CoV-2 Antigen Rapid Diagnostic Tests in Various Clinical Settings. *medRxiv* 2021.03.02.21252400 (2021) doi:10.1101/2021.03.02.21252400.
64. Smithgall, M. C., Scherberkova, I., Whittier, S. & Green, D. A. Comparison of Cepheid Xpert Xpress and Abbott ID Now to Roche cobas for the Rapid Detection of SARS-CoV-2. *J Clin Virol* **128**, 104428 (2020).
65. Loeffelholz, M. J. *et al.* Multicenter Evaluation of the Cepheid Xpert Xpress SARS-CoV-2 Test. *J Clin Microbiol* **58**, (2020).
66. Wolters, F. *et al.* Multi-center evaluation of cepheid xpert® xpress SARS-CoV-2 point-of-care test during the SARS-CoV-2 pandemic. *Journal of Clinical Virology* **128**, 104426 (2020).
67. Moeren, N. V. der *et al.* PERFORMANCE EVALUATION OF A SARS-COV-2 RAPID ANTIGENTEST: TEST PERFORMANCE IN THE COMMUNITY IN THE NETHERLANDS. *medRxiv* 2020.10.19.20215202 (2020) doi:10.1101/2020.10.19.20215202.
68. Peña, M. *et al.* Performance of SARS-CoV-2 rapid antigen test compared with real-time RT-PCR in asymptomatic individuals. *medRxiv* 2021.02.12.21251643 (2021) doi:10.1101/2021.02.12.21251643.
69. Hansen, G. *et al.* Clinical Performance of the Point-of-Care cobas Liat for Detection of SARS-CoV-2 in 20 Minutes: a Multicenter Study. *J Clin Microbiol* **59**, (2021).
70. Gibani, M. M. *et al.* Assessing a novel, lab-free, point-of-care test for SARS-CoV-2 (CovidNudge): a diagnostic accuracy study. *The Lancet Microbe* **1**, e300–e307 (2020).
71. Donato, L. J. *et al.* Evaluation of the Cue Health point-of-care COVID-19 (SARS-CoV-2 nucleic acid amplification) test at a community drive through collection center. *Diagn Microbiol Infect Dis* **100**, 115307 (2021).
72. Cradic, K. *et al.* Clinical Evaluation and Utilization of Multiple Molecular In Vitro Diagnostic Assays for the Detection of SARS-CoV-2. *American Journal of Clinical Pathology* **154**, 201–207 (2020).
73. DnaNudge: CovidNudge: rapid, lab-free COVID-19 test. <https://www.dnanudge.com/en/COVID-Nudge>.
74. MOBIDIAG. Instructions for Use for the Novodiag® System. (2020).
75. Mobidiag - Molecular diagnostics of coronavirus infection. *Mobidiag* <https://mobidiag.com/products/coronavirus/>.

76. Health, C. for D. and R. Potential for False Results with Roche Molecular Systems, Inc. cobas SARS-CoV-2 & Influenza Test for use on cobas Liat System-Letter to Clinical Laboratory Staff, Point-of-Care Facility Staff, and Health Care Providers. *FDA* (2021).
77. Coronavirus COVID-19 serology and viral detection tests: technical validation reports. *GOV.UK* <https://www.gov.uk/government/publications/coronavirus-covid-19-serology-and-viral-detection-tests-technical-validation-reports>.
78. Visseaux, B. *et al.* Evaluation of the QIAstat-Dx Respiratory SARS-CoV-2 Panel, the First Rapid Multiplex PCR Commercial Assay for SARS-CoV-2 Detection. *J Clin Microbiol* **58**, (2020).
79. Österdahl, M. F. *et al.* Detecting SARS-CoV-2 at point of care: preliminary data comparing loop-mediated isothermal amplification (LAMP) to polymerase chain reaction (PCR). *BMC Infectious Diseases* **20**, 783 (2020).
80. Fitoussi, F., Dupont, R., Tonen-Wolyec, S. & Bélec, L. Performances of the VitaPCR™ SARS-CoV-2 Assay during the second wave of the COVID-19 epidemic in France. *Journal of Medical Virology* **n/a**,.
81. Diagnostics for the Real World. SAMBA II SARS-CoV-2 Test Instructions for use. (2021).
82. VitaPCRTM Platform. <https://www.mediconire.com/vitapcrtm-platform>.
83. Xpert® Xpress SARS-CoV-2 has received FDA Emergency Use Authorization. <https://www.cepheid.com/coronavirus>.
84. QIAstat-Dx Analyzer 1.0 User Manual - QIAGEN. <https://www.qiagen.com/us/resources/resourcedetail?id=658139de-0b59-4801-a1fd-92d4cd75da3f&lang=en>.
85. Products Archive. *MicrosensDx* <https://www.microsensdx.com/product/>.
86. Schwob, J. M. *et al.* Antigen rapid tests, nasopharyngeal PCR and saliva PCR to detect SARS-CoV-2: a prospective comparative clinical trial. *medRxiv* 2020.11.23.20237057 (2020) doi:10.1101/2020.11.23.20237057.
87. Pollock, N. R. *et al.* Performance and Implementation Evaluation of the Abbott BinaxNOW Rapid Antigen Test in a High-Throughput Drive-Through Community Testing Site in Massachusetts. *J Clin Microbiol* **59**, (2021).
88. Baro, B. *et al.* Performance characteristics of five antigen-detecting rapid diagnostic test (Ag-RDT) for SARS-CoV-2 asymptomatic infection: a head-to-head benchmark comparison. *medRxiv* 2021.02.11.21251553 (2021) doi:10.1101/2021.02.11.21251553.
89. Torres, I., Poujois, S., Albert, E., Colomina, J. & Navarro, D. Evaluation of a rapid antigen test (Panbio™ COVID-19 Ag rapid test device) for SARS-CoV-2 detection in asymptomatic close contacts of COVID-19 patients. *Clinical Microbiology and Infection* **27**, 636.e1-636.e4 (2021).
90. Wagenhäuser, I. *et al.* Clinical performance evaluation of SARS-CoV-2 rapid antigen testing in point of care usage in comparison to RT-qPCR. *medRxiv* 2021.03.27.21253966 (2021) doi:10.1101/2021.03.27.21253966.

91. Masiá, M. *et al.* Nasopharyngeal Panbio COVID-19 Antigen Performed at Point-of-Care Has a High Sensitivity in Symptomatic and Asymptomatic Patients With Higher Risk for Transmission and Older Age. *Open Forum Infectious Diseases* **8**, (2021).
92. Drevinek, P. *et al.* The sensitivity of SARS-CoV-2 antigen tests in the view of large-scale testing. *medRxiv* 2020.11.23.20237198 (2020) doi:10.1101/2020.11.23.20237198.
93. Bulilete, O. *et al.* Evaluation of the Panbio™ rapid antigen test for SARS-CoV-2 in primary health care centers and test sites. *medRxiv* 2020.11.13.20231316 (2020) doi:10.1101/2020.11.13.20231316.
94. Linares, M. *et al.* Panbio antigen rapid test is reliable to diagnose SARS-CoV-2 infection in the first 7 days after the onset of symptoms. *J Clin Virol* **133**, 104659 (2020).
95. Landaas, E. T. *et al.* Diagnostic performance of a SARS-CoV-2 rapid antigen test in a large, Norwegian cohort. *J Clin Virol* **137**, 104789 (2021).
96. Albert, E. *et al.* Field evaluation of a rapid antigen test (Panbio™ COVID-19 Ag Rapid Test Device) for COVID-19 diagnosis in primary healthcare centres. *Clin Microbiol Infect* **27**, 472.e7-472.e10 (2021).
97. Abdulrahman, A. *et al.* Comparison of SARS-COV-2 nasal antigen test to nasopharyngeal RT-PCR in mildly symptomatic patients. *medRxiv* 2020.11.10.20228973 (2020) doi:10.1101/2020.11.10.20228973.
98. Faíco-Filho, K. S. *et al.* Evaluation of the Panbio™ COVID-19 Ag Rapid Test at an Emergency Room in a Hospital in São Paulo, Brazil. *medRxiv* 2021.03.15.21253313 (2021) doi:10.1101/2021.03.15.21253313.
99. Berger, A. *et al.* Diagnostic accuracy of two commercial SARS-CoV-2 Antigen-detecting rapid tests at the point of care in community-based testing centers. *medRxiv* 2020.11.20.20235341 (2020) doi:10.1101/2020.11.20.20235341.
100. Krüger, L. J. *et al.* Evaluation of the accuracy and ease-of-use of Abbott PanBio - A WHO emergency use listed, rapid, antigen-detecting point-of-care diagnostic test for SARS-CoV-2. *medRxiv* 2020.11.27.20239699 (2020) doi:10.1101/2020.11.27.20239699.
101. Stokes, W. *et al.* Clinical performance of the Abbott Panbio with nasopharyngeal, throat, and saliva swabs among symptomatic individuals with COVID-19. *Eur J Clin Microbiol Infect Dis* 1–6 (2021) doi:10.1007/s10096-021-04202-9.
102. Merino, P. *et al.* Multicenter evaluation of the Panbio™ COVID-19 rapid antigen-detection test for the diagnosis of SARS-CoV-2 infection. *Clinical Microbiology and Infection* **27**, 758–761 (2021).
103. Koskinen, J. M. *et al.* Clinical Validation of Automated and Rapid mariPOC SARS-CoV-2 Antigen Test. *medRxiv* 2021.02.08.21250086 (2021) doi:10.1101/2021.02.08.21250086.
104. COVID-VIRO | COVID-19 AAZ. <https://www.covid19aaz.com/en/rapide-antigenic-test/> (2020).
105. Abbott. Panbio™ COVID-19 Ag Rapid Test Device. (2021).
106. COVID-19 tests - mariPOC. <https://www.arcadia.com/maripoc/tests/covid-19-tests/>.

107. Krüger, L. J. *et al.* Evaluation of the accuracy, ease of use and limit of detection of novel, rapid, antigen-detecting point-of-care diagnostics for SARS-CoV-2. *medRxiv* 2020.10.01.20203836 (2020) doi:10.1101/2020.10.01.20203836.
108. Cheung, N. N. *et al.* On-site rapid molecular testing, mobile sampling teams and eHealth to support primary care physicians during the COVID-19 pandemic. *medRxiv* 2020.11.20.20234898 (2020) doi:10.1101/2020.11.20.20234898.
109. Lambert-Niclot, S. *et al.* Evaluation of a Rapid Diagnostic Assay for Detection of SARS-CoV-2 Antigen in Nasopharyngeal Swabs. *J Clin Microbiol* **58**, (2020).
110. Takeuchi, Y. *et al.* The evaluation of a newly developed antigen test (QuickNavi™-COVID19 Ag) for SARS-CoV-2: A prospective observational study in Japan. *Journal of Infection and Chemotherapy* **27**, 890–894 (2021).
111. Houston, H., Gupta-Wright, A., Toke-Bjolgerud, E., Biggin-Lamming, J. & John, L. Diagnostic accuracy and utility of SARS-CoV-2 antigen lateral flow assays in medical admissions with possible COVID-19. *Journal of Hospital Infection* **110**, 203–205 (2021).
112. CORIS. COVID-19 Ag Respi-Strip. (2020).
113. Fujirebio. ESPLINE SARS-CoV-2. (2021).
114. Innova. SARS-CoV-2 Antigen Rapid Qualitative Test Instructions for Use. (2020).
115. Krüger, L. J. *et al.* Evaluation of accuracy, exclusivity, limit-of-detection and ease-of-use of LumiraDx™-Antigen-detecting point-of-care device for SARS-CoV-2. *medRxiv* 2021.03.02.21252430 (2021) doi:10.1101/2021.03.02.21252430.
116. Drain, P. K. *et al.* A Rapid, High-Sensitivity SARS-CoV-2 Nucleocapsid Immunoassay to Aid Diagnosis of Acute COVID-19 at the Point of Care: A Clinical Performance Study. *Infect Dis Ther* **10**, 753–761 (2021).
117. Lepu Medical. SARS-CoV-2 Antigen Rapid Test Kit (Colloidal Gold Immunochromatography). (2020).
118. MEDsan. MEDsan SARS-CoV-2 Antigen Rapid Test. (2021).
119. ApS, A., Lora Grafisk. PCL Covid19 Ag Gold Saliva. *Vitrex* <https://vitrexmedical.com/covid-19-products/covid-19-test-kits/pcl-covid-19-ag-gold-saliva/>.
120. Health, C. for D. and R. Lepu Medical Technology Recalls SARS-CoV-2 Antigen Rapid Test Kit and Leccurate SARS-CoV-2 Antibody Rapid Test Kit (Colloidal Gold Immunochromatography) due to Risk of False Results. *FDA* (2021).
121. Iglói, Z. *et al.* Clinical Evaluation of Roche SD Biosensor Rapid Antigen Test for SARS-CoV-2 in Municipal Health Service Testing Site, the Netherlands - Volume 27, Number 5—May 2021 - *Emerging Infectious Diseases journal* - CDC. doi:10.3201/eid2705.204688.

122. Torres, I. *et al.* Point-of-care evaluation of a rapid antigen test (CLINITEST® Rapid COVID-19 Antigen Test) for diagnosis of SARS-CoV-2 infection in symptomatic and asymptomatic individuals. *Journal of Infection* **82**, e11–e12 (2021).
123. Shidlovskaya, E. V. *et al.* The Value of Rapid Antigen Tests to Identify Carriers of Viable SARS-CoV-2. *medRxiv* 2021.03.10.21252667 (2021) doi:10.1101/2021.03.10.21252667.
124. Biocredit. COVID-19 Ag. (2020).
125. Roche SARS-CoV 2 Rapid Antigen Test x 25 (For COVID-19). *UK Medisave UK View* <https://www.medisave.co.uk/roche-sars-cov-2-rapid-anti-gen-test-kit.html>.
126. SD Biosensor, Inc. STANDARD Q COVID-19 Ag Test. (2020).
127. SIEMENS. CLINITEST® Rapid COVID-19 Antigen Test. (2021).
128. Sugentech. <http://www.sugentech.com/>.
129. Haage, V. *et al.* Impaired performance of SARS-CoV-2 antigen-detecting rapid tests at elevated temperatures. <http://medrxiv.org/lookup/doi/10.1101/2021.01.06.21249314> (2021) doi:10.1101/2021.01.06.21249314.
130. Bourassa, L. *et al.* A SARS-CoV-2 Nucleocapsid Variant that Affects Antigen Test Performance. 2021.05.05.21256527 <https://www.medrxiv.org/content/10.1101/2021.05.05.21256527v1> (2021) doi:10.1101/2021.05.05.21256527.
131. Kriemler, S. *et al.* Surveillance of Acute SARS-CoV-2 Infections in School Children and Point-Prevalence During a Time of High Community Transmission in Switzerland. *Front. Pediatr.* **9**, (2021).
132. Clark, T. W. *et al.* Diagnostic accuracy of a host response point-of-care test in patients with suspected COVID-19. *medRxiv* 2020.05.27.20114512 (2020) doi:10.1101/2020.05.27.20114512.
133. Houston, H. *et al.* Use of the FebriDx point-of-care assay as part of a triage algorithm for medical admissions with possible COVID-19. *medRxiv* 2021.01.05.21249154 (2021) doi:10.1101/2021.01.05.21249154.
134. Ismail, S. A. *et al.* Horses for courses? Assessing the potential value of a surrogate, point-of-care test for SARS-CoV-2 epidemic control. *Influenza and Other Respiratory Viruses* **15**, 3–6 (2021).
135. Karim, N. *et al.* Utility of the FebriDx point-of-care test for rapid triage and identification of possible coronavirus disease 2019 (COVID-19). *International Journal of Clinical Practice* **75**, e13702 (2021).

Identification

Articles identified through PubMed search (n= 345)

Articles identified through MedRxiv search (n= 365)

Articles identified through BioRxiv search (n= 54)

Screening

Articles screened (n= 871)

Articles excluded: duplicates, unrelated topic (i.e, seroprevalence, reviews, risk scores, prognostic scores, imaging scores), test does not focus on acute diagnosis (e.g antibody assays) or uses imaging techniques (e.g, point-of-care ultrasound)

Eligibility

Articles screened for full reading (n= 261)

Articles excluded: Not point-of-care, laboratory-only evaluations, selected population, assay not compared to PCR. Debate between authors for articles with high heterogeneity in methods

Inclusion

Articles included in systematic review (n= 51)